Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory AffairsHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory AffairsPR NewswireJanuary 7, 2020ReblogShareTweetShareSTOCKHOLM, Jan. 7, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karin Eklund Vanderpol has been appointed as head of regulatory affairs of Oncopeptides. Karin has 20 years of experience from senior positions in regulatory affairs. Prior to joining Oncopeptides, she served as Global Regulatory Director at Swedish Orphan Biovitrum. She will be a member Oncopeptides' Management Team and will start today. Elisabeth Augustsson, who has been responsible for Oncopeptides' regulatory function since 2015 will continue in a senior role in the regulatory team.For more information, please contact: Jakob LindbergCEO of OncopeptidesE-mail: jakob.lindberg@oncopeptides.com  Telephone: +46-8-615-20-40Rein PiirHead of Investor Relations at Oncopeptides E-mail: rein.piir@oncopeptides.com  Cell phone: +46-70-853-72-92This information was submitted for publication at 08.00 CET January 7, 2020.About OncopeptidesOncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides' headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.More information is available on www.oncopeptides.com.This information was brought to you by Cision http://news.cision.comhttps://news.cision.com/oncopeptides-ab/r/oncopeptides-strengthens-its-regulatory-function-by-appointing-karin-eklund-vanderpol-as-head-of-reg,c3002258The following files are available for download: https://mb.cision.com/Main/15404/3002258/1170538.pdf
Press Release - New Head of Regulatory January 7, 2020
CisionMoreView original content:http://www.prnewswire.com/news-releases/oncopeptides-strengthens-its-regulatory-function-by-appointing-karin-eklund-vanderpol-as-head-of-regulatory-affairs-300982348.htmlSOURCE Oncopeptides ABReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloomberg'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinancePresidential historian Doug Wead on Trump's impeachmentYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance VideoSpaceX is set to offer tourists a 5-day flight in its Crew Dragon CapsuleYahoo Finance Video